Advertisement

ASS und NSAR – Unter Behandlung mit ASS 100 mg bei KHK/pAVK soll vor Beginn einer NSAR-Therapie das Interaktionspotenzial bedacht werden

ASA and NSAID—in patients treated with 100 mg ASA for CAD/PAD, potential interactions should be considered before initiating NSAID treatment

  • 19 Accesses

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Literatur

  1. 1.

    Kohli P, Steg PG, Cannon CP et al (2014) NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med 127:53–60.e1

  2. 2.

    Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase‑2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906–2913

  3. 3.

    Nissen SE, Yeomans ND, Solomon DH et al (2016) Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375:2519–2529

  4. 4.

    Reed GW, Abdallah MS, Shao M et al (2018) Effect of aspirin coadministration on the safety of celecoxib, naproxen, or ibuprofen. J Am Coll Cardiol 71:1741–1751

  5. 5.

    Reed GW, Nissen SE (2019) NSAID choice: lessons from PRECISION. Aging 11:2181–2182

  6. 6.

    Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817

  7. 7.

    Saxena A, Balaramnavar VM, Hohlfeld T et al (2013) Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol 721:215–224

  8. 8.

    Gladding PA, Webster MWI, Farrell HB et al (2008) The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101:1060–1063

  9. 9.

    Van Ryn J, Kink-Eiband M, Kuritsch I et al (2004) Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 44:777–784

  10. 10.

    Wilner KD, Rushing M, Walden C et al (2002) Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 42:1027–1030

Download references

Author information

Correspondence to Prof. Dr. Tobias Geisler.

Ethics declarations

Interessenkonflikt

T. Geisler und T. Wieland geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Geisler, T., Wieland, T. ASS und NSAR – Unter Behandlung mit ASS 100 mg bei KHK/pAVK soll vor Beginn einer NSAR-Therapie das Interaktionspotenzial bedacht werden. Kardiologe (2020). https://doi.org/10.1007/s12181-019-00363-2

Download citation